$CUR Headlines Neuralstem gets FDA okay for depression

New Post Public Reply Private Reply Replies (0) Message Board

Jun 25, 2014 at 12:28 PM

$CUR Headlines

Neuralstem gets FDA okay for depression study 10:28 a.m. Oct. 17, 2012 - MarketWatch.com
Stocks to watch Monday: LDK, OfficeMax 5:27 p.m. Sept. 14, 2012 - William Spain
Friday’s biggest gaining and declining stocks 5:11 p.m. Sept. 14, 2012 - MarketWatch
Hot stocks to watch 7:14 a.m. Sept. 14, 2012 - MarketWatch.com
Stocks to watch Friday: Werner, Libbey, Delphi 7:07 a.m. Sept. 14, 2012 - MarketWatch
Canada hot stocks: Scotiabank, Great Panther 3:29 p.m. Aug. 30, 2011 - MarketWatch
Are stem-cell stocks a good buy? 3:06 p.m. July 13, 2011 - Val Brickates Kennedy
Drug stocks mixed after Fed statement 2:02 p.m. June 22, 2011 - Val Brickates Kennedy
Drug stocks gain while Nanosphere sinks 2:12 p.m. June 21, 2011 - Val Brickates Kennedy
Neuralstem soars on FDA move 3:00 p.m. Feb. 9, 2011 - Val Brickates Kennedy
Neuralstem, Impax in drug-sector spotlight 4:22 p.m. Dec. 16, 2010 - Val Brickates Kennedy
Neuralstem climbs as drug indexes hug flat line 11:02 a.m. Dec. 16, 2010 - Val Brickates Kennedy
Neuralstem soars on FDA nod 10:16 a.m. Dec. 16, 2010 - Val Brickates Kennedy
Before the Close Report from the MarketWatch Radio Network 2:31 p.m. March 9, 2009 - Andrew O'Day
Geron's study OK signals progress for company, stem cell peers 2:13 p.m. Jan. 23, 2009 - MarketWatch.com
2007 could emerge as a pivotal year for stem-cell investing 6:43 p.m. Dec. 12, 2007 - Scott Austin
Palatin plunges on drug setback; Atherogenics continues rally 1:42 p.m. Aug. 30, 2007 - Val Brickates Kennedy
Neuralstem teams up with U Mich. for ALS research 9:26 a.m. Aug. 30, 2007 - Val Brickates Kennedy
Stem cell industry trying to see silver lining in funding fight 12:36 p.m. April 13, 2007 - Greg Presto

BrainStorm Tackles Neurodegenerative Diseases With Novel Cell Therapy 1:44 p.m. June 12, 2014 - Seeking Alpha
Neuralstem NSI-189 Abstract Teases At Potential Greatness 9:14 a.m. May 28, 2014 - Seeking Alpha
Interesting CUR Put And Call Options For July 19th 12:10 p.m. May 19, 2014 - TheStreet.com
A trader's look at Neuralstem 3:07 p.m. May 14, 2014 - Seeking Alpha
10-Q: NEURALSTEM, INC. 6:29 a.m. May 12, 2014 - Edgar Online - (EDG = 10Q, 10K)
BrainStorm to start Phase 2 ALS trial 10:12 a.m. April 28, 2014 - Seeking Alpha
Interesting CUR Put And Call Options For June 21st 11:54 a.m. April 22, 2014 - TheStreet.com
Neuralstem's Cell Therapy Is Working, And This Is Just The Beginning 8:41 a.m. April 22, 2014 - Seeking Alpha
Stem cell trial for spinal cord injury to proceed 10:02 a.m. April 16, 2014 - Seeking Alpha
Aastrom: Mice Scared Me Away 10:51 a.m. March 26, 2014 - Seeking Alpha
Senators introduce regenerative medicine bill 1:40 p.m. March 14, 2014 - Seeking Alpha
Neuralstem And Brainstorm Cell Therapeutics: The Race To Treat ALS 10:30 a.m. March 11, 2014 - Seeking Alpha
Osiris Therapeutics: Poised For Another Breakout 2:07 a.m. March 11, 2014 - Seeking Alpha
Major stem cell discovery might not be so major 2:32 p.m. March 10, 2014 - Seeking Alpha
10-K: NEURALSTEM, INC. 6:30 a.m. March 10, 2014 - Edgar Online - (EDG = 10Q, 10K)
An Early Valuation Of Neuralstem's NSI566 10:25 a.m. Feb. 28, 2014 - Seeking Alpha
Neuralstem Phase 1 Data Gives Hope In ALS 12:46 p.m. Feb. 18, 2014 - Seeking Alpha
StemCells, Inc., And Neuralstem, Inc.: A Side-By-Side Analysis 2:17 p.m. Jan. 31, 2014 - Seeking Alpha
Neuralstem: Sizing Up Potential Key Events Of 2014 9:05 a.m. Jan. 28, 2014 - Seeking Alpha
Neuralstem, StemCells, Inc., And Athersys, Inc. - Making Early Headlines In 2014 10:30 a.m. Jan. 24, 2014 - Seeking Alpha

Neuralstem's NSI-189 Novel Neurogenic Compound Shows Significant Effect In Major Depressive Disorder 9:15 a.m. Today - PR Newswire - PRF
Neuralstem NSI-189 Select Data To Be Presented At Neuropsychopharmacology Congress 9:15 a.m. June 19, 2014 - PR Newswire - PRF
Neuralstem Final Phase I Depression Data Presented At The American Society Of Clinical Psychopharmacology Annual Meeting 9:15 a.m. June 18, 2014 - PR Newswire - PRF
Neuralstem, Inc. - "The FDA is Not the Enemy" 9:26 a.m. June 9, 2014 - ACCESSWIRE
Morning Briefing on Top Gainers -- Research on GTx Inc., Iridium Communications, Neuralstem, and Idera Pharma 6:50 a.m. May 29, 2014 - PR Newswire - PRF
Neuralstem, Inc. - "Most men would rather deny a hard truth than face it" 11:36 a.m. May 28, 2014 - ACCESSWIRE
Neuralstem Depression Trial Data to Be Presented at The American Society of Clinical Psychopharmacology Annual Meeting 9:28 a.m. May 23, 2014 - PR Newswire - PRF
Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update 9:15 a.m. May 12, 2014 - PR Newswire - PRF
Technical Data on Top Gainers -- Research on Assured Guaranty, Ampio Pharma, Neuralstem, and Kennedy-Wilson Holdings 1:34 p.m. May 9, 2014 - PR Newswire - PRF
Neuralstem Appoints Sandford Drexel Smith, Former Genzyme Executive Vice President, To Board Of Directors 9:15 a.m. May 8, 2014 - PR Newswire - PRF
Neuralstem Spinal Cord Injury Stem Cell Trial Approved To Commence At University Of California, San Diego 9:15 a.m. April 16, 2014 - PR Newswire - PRF
Equities Updates on Top Gainers -- Research on E-Commerce China Dangdang, Neuralstem, Cytokinetics, and Nu Skin Enterprises 1:30 p.m. April 10, 2014 - PR Newswire - PRF
Neuralstem Principal Investigator, Dr. Eva Feldman, To Present Published ALS Trial Phase I Data At Medical Conference 9:15 a.m. April 7, 2014 - PR Newswire - PRF
Study Shows Neuralstem Cells Transplanted Into Brain Significantly Improve Post-Stroke Symptoms in Rats 9:15 a.m. March 28, 2014 - PR Newswire - PRF
Equities Recording New Highs: Generac Holding, Sempra Energy, Neuralstem, and Great Plains Energy 9:41 a.m. March 18, 2014 - PR Newswire - PRF
Final Results Of Neuralstem Phase I Stem Cell Trial In Amyotrophic Lateral Sclerosis Published In Annals of Neurology 9:15 a.m. March 17, 2014 - PR Newswire - PRF
Breakthroughs on the Horizon for CTE and Other Neurodegenerative Diseases 1:22 p.m. March 13, 2014 - ACCESSWIRE
Discovery Could Lead to Major Breakthrough in Alzheimer's Disease and Other Brain Disorders 2:31 p.m. March 5, 2014 - ACCESSWIRE
Neuralstem, Inc. "Right to Try" 10:45 a.m. March 3, 2014 - ACCESSWIRE
Neuralstem President and CEO to Present NSI-566 Clinical Trials Program Update at BIO CEO & Investor Conference 2014 10:00 a.m. Feb. 6, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...